Hasimu Asihaer, Gu Jun-Peng, Ji Wei-Zheng, Zhang Hai-Xiao, Zhu Di-Wen, Ren Wei-Xin
Department of Radiology, The First Affiliated Hospital of XinJiang Medical University, Urumqi, XinJiang830054, China.
Department of Radiology, The First Affiliated Hospital of XinJiang Medical University, Urumqi, XinJiang830054, China.
J Vasc Interv Radiol. 2017 Apr;28(4):583-593. doi: 10.1016/j.jvir.2016.11.038. Epub 2017 Feb 2.
To prospectively evaluate safety and efficacy of biliary stent placement with iodine-125 (I) seeds in patients with malignant obstructive jaundice (MOJ).
From July 2011 to June 2014, 55 patients were enrolled (group A, 11 men and 17 women, mean age 70.93 y ± 8.58; group B, 14 men and 13 women, mean age 70.26 y ± 9.71). All patients were randomly assigned to placement of a biliary stent with I seeds (group A) or biliary stent only (group B). After stent placement, outcomes were measured regarding relief of MOJ. Clinical success rate, survival time, and safety were recorded. P < .05 was considered to indicate significant difference.
Stents were successfully placed in all 55 patients. MOJ was relieved in all patients, and there were no significant differences in complications related to stent insertion between the 2 groups. Mean and median stent patency were 191 days ± 19.8 (95% confidence interval [CI], 152-230 d) and 179 days ± 191.4 (95% CI, 87-267 d) in group A and 88.3 days ± 16.3 (95% CI, 61-114 d) and 77 days ± 88.2 (95% CI, 65-86 d) in group B (P < .001, log-rank test). Mean and median survival time were 222.6 days ± 21.0 (95% CI, 181-263 d) and 241 days ± 18.2 (95% CI, 179-270 d) in group A and 139.1 days ± 14.5 (95% CI, 110-167 d) and 142 days ± 16.3 (95% CI, 83-177 d) in group B (P < .001, log-rank test).
I seeds combined with biliary stent placement could significantly improve stent patency. The procedure seems to be safe and to extend survival compared with self-expandable biliary stent placement.
前瞻性评估碘-125(I)粒子胆道支架置入术治疗恶性梗阻性黄疸(MOJ)患者的安全性和有效性。
2011年7月至2014年6月,共纳入55例患者(A组,男11例,女17例,平均年龄70.93岁±8.58岁;B组,男14例,女13例,平均年龄70.26岁±9.71岁)。所有患者随机分为碘粒子胆道支架置入组(A组)和单纯胆道支架置入组(B组)。支架置入后,评估MOJ缓解情况。记录临床成功率、生存时间和安全性。P <.05被认为具有显著差异。
55例患者均成功置入支架。所有患者的MOJ均得到缓解,两组间与支架置入相关的并发症无显著差异。A组支架平均通畅时间和中位通畅时间分别为191天±19.8(95%置信区间[CI],152 - 230天)和179天±191.4(95%CI,87 - 267天),B组分别为88.3天±16.3(95%CI,61 - 114天)和77天±88.2(95%CI,65 - 86天)(P <.001,对数秩检验)。A组平均生存时间和中位生存时间分别为222.6天±21.0(95%CI,181 - 263天)和241天±18.2(95%CI,179 - 270天),B组分别为139.1天±14.5(95%CI,110 - 167天)和142天±16.3(95%CI,83 - 177天)(P <.001,对数秩检验)。
碘粒子联合胆道支架置入可显著提高支架通畅率。与自膨式胆道支架置入相比,该方法似乎安全且能延长生存期。